Wnt / bgr-Catenin Signaling Pathway as Novel Cancer Drug Targets

Authors: Hue H. Luu1; Ruiwen Zhang1; Rex C. Haydon1; Elizabeth Rayburn1; Quan Kang1; Weike Si1; Jong K. Park1; Hui Wang1; Ying Peng1; Wei Jiang1; Tong- C.h.u.a.n. He1

Source: Current Cancer Drug Targets, Volume 4, Number 8, December 2004 , pp. 653-671(19)

Publisher: Bentham Science Publishers

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Wnt proteins are a large family of secreted glycoproteins. Wnt proteins bind to the Frizzled receptors and LRP5/6 co-receptors, and through stabilizing the critical mediator bgr-catenin, initiate a complex signaling cascade that plays an important role in regulating cell proliferation and differentiation. Deregulation of the canonical Wnt/bgr-catenin signaling pathway, mostly by inactivating mutations of the APC tumor suppressor, or oncogenic mutations of bgr-catenin, has been implicated in colorectal tumorigenesis. Although oncogenic mutations of bgr-catenin have only been discovered in a small fraction of non-colon cancers, elevated levels of bgr- catenin protein, a hallmark of activated canonical Wnt pathway, have been observed in most common forms of human malignancies, indicating that activation of this pathway may play an important role in tumor development. Over the past 15 years, our understanding of this signaling pathway has significantly improved with the identification of key regulatory proteins and the important downstream targets of bgr-catenin/Tcf transactivation complex. Given the fact that Wnt/bgr-catenin signaling is tightly regulated at multiple cellular levels, the pathway itself offers ample targeting nodal points for cancer drug development. In this review, we discuss some of the strategies that are being used or can be explored to target key components of the Wnt/bgr- catenin signaling pathway in rational cancer drug discovery.

Keywords: wnt; catenin; signal transduction; tumorigenesis; cancer targets; high throughput screening

Document Type: Review article

DOI: 10.2174/1568009043332709

Affiliations: 1: Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, 5841 South Maryland Avenue, MC3079, Chicago, IL 60637, USA.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$55.10 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A